Population genomics of pneumococcal carriage in South Africa following the introduction of the 13-valent pneumococcal conjugate vaccine (PCV13) immunization

被引:7
|
作者
Javaid, Nida [1 ,2 ]
Olwagen, Courtney [3 ,4 ]
Nzenze, Susan [3 ,4 ]
Hawkins, Paulina [5 ]
Gladstone, Rebecca [2 ]
McGee, Lesley [5 ]
Breiman, Robert F. [6 ]
Bentley, Stephen D. [2 ,7 ]
Madhi, Shabir A. [3 ,4 ]
Lo, Stephanie [2 ]
机构
[1] Lahore Univ Management Sci, Syed Babar Ali Sch Sci & Engn, Dept Biol, Lahore, Pakistan
[2] Wellcome Sanger Inst, Parasites & Microbes, Hinxton, England
[3] Univ Witwatersrand, Natl Res Fdn Vaccine Preventable Dis, Dept Sci & Technol, Johannesburg, South Africa
[4] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Med Res Council Resp & Meningeal Pathogens Res Un, Johannesburg, South Africa
[5] Ctr Dis Control & Prevent, Atlanta, GA USA
[6] Emory Global Hlth Inst, Atlanta, GA USA
[7] Univ Cambridge, Dept Pathol, Cambridge, England
来源
MICROBIAL GENOMICS | 2022年 / 8卷 / 06期
关键词
antimicrobial resistance; pneumococci; pneumococcal carriage; pneumococcal conjugate vaccine; pneumococcal genomics; TEMPORAL-CHANGES; COLONIZATION; DISEASE;
D O I
10.1099/mgen.0.000831
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Streptococcus pneumoniae is a major human pathogen responsible for over 317000 deaths in children <5 years of age with the burden of the disease being highest in low-and middle-income countries including South Africa. Following the introduction of the 7-valent and 13-valent pneumococcal conjugate vaccine (PCV) in South Africa in 2009 and 2011, respectively, a decrease in both invasive pneumococcal infections and asymptomatic carriage of vaccine -type pneumococci were reported. In this study, we described the changing epidemiology of the pneumococcal carriage population in South Africa, by sequencing the genomes of 1825 isolates collected between 2009 and 2013. Using these genomic data, we reported the changes in serotypes, Global Pneumococ-cal Sequence Clusters (GPSCs), and antibiotic resistance before and after the introduction of PCV13. The pneumococcal carriage population in South Africa has a high level of diversity, comprising of 126 GPSCs and 49 serotypes. Of the ten most prevalent GPSCs detected, six were predominantly found in Africa (GPSC22, GPSC21, GPSC17, GPSC33, GPSC34 and GPSC52). We found a significant decrease in PCV7 serotypes (19F, 6B, 23F and 14) and an increase in non-vaccine serotypes (NVT) (16F, 34, 35B and 11A) among children <2 years of age. The increase in NVTs was driven by pneumococcal lineages GPSC33, GPSC34, GPSC5 and GPSC22. Overall, a decrease in antibiotic resistance for 11 antimicrobials was detected in the PCV13 era. Further, we reported a higher resistance prevalence among vaccine types (VTs), as compared to NVTs; however, an increase in penicillin resistance among NVT was observed between the PCV7 and PCV13 eras. The carriage isolates from South Africa predominantly belonged to pneumococcal lineages, which are endemic to Africa. While the introduction of PCV resulted in an overall reduction of resistance in pneumococcal carriage isolates, an increase in penicillin resistance among NVTs was detected in children aged between 3 and 5 years, driven by the expan-sion of penicillin-resistant clones associated with NVTs in the PCV13 era.
引用
下载
收藏
页数:9
相关论文
共 50 条
  • [1] 13-valent pneumococcal conjugate vaccine (PCV13)
    Jefferies, Johanna M. C.
    Macdonald, Emily
    Faust, Saul N.
    Clarke, Stuart C.
    HUMAN VACCINES, 2011, 7 (10): : 1012 - 1018
  • [2] Impact of the 13-valent pneumococcal conjugate vaccine (pcv13) on invasive pneumococcal disease and carriage in Alaska
    Bruce, Michael G.
    Singleton, Rosalyn
    Bulkow, Lisa
    Rudolph, Karen
    Zulz, Tammy
    Gounder, Prabhu
    Hurlburt, Debby
    Bruden, Dana
    Hennessy, Thomas
    VACCINE, 2015, 33 (38) : 4813 - 4819
  • [3] Non-vaccine serotype pneumococcal carriage in healthy infants in South Africa following introduction of the 13-valent pneumococcal conjugate vaccine
    Skosana, Z.
    von Gottberg, A.
    Olorunju, S.
    Mohale, T.
    du Plessis, M.
    Adams, T.
    Mbelle, N.
    SAMJ SOUTH AFRICAN MEDICAL JOURNAL, 2021, 111 (02): : 143 - 148
  • [4] 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Preterm Versus Term Infants
    Martinon-Torres, Federico
    Czajka, Hanna
    Center, Kimberly J.
    Wysocki, Jacek
    Majda-Stanislawska, Ewa
    Omenaca, Felix
    Bernaola Iturbe, Enrique
    Blazquez Gamero, Daniel
    Concheiro-Guisan, Ana
    Gimenez-Sanchez, Francisco
    Szenborn, Leszek
    Giardina, Peter C.
    Patterson, Scott
    Gruber, William C.
    Scott, Daniel A.
    Gurtman, Alejandra
    PEDIATRICS, 2015, 135 (04) : E876 - E886
  • [5] 13-valent pneumococcal conjugate vaccine in Africa
    Cohen, Robert
    Levy, Corinne
    LANCET GLOBAL HEALTH, 2017, 5 (03): : E244 - E245
  • [6] Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Beutels, P.
    McIntyre, P.
    Menzies, R.
    Reyes, J. F.
    Chen, C.
    Newall, A. T.
    VACCINE, 2017, 35 (34) : 4307 - 4314
  • [7] A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Newall, A. T.
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2015, 11 (04) : 818 - 825
  • [8] Clinical and Demographic Characteristics of an Expanded Target Population for 13-Valent Pneumococcal Conjugate Vaccine (Prevnar 13®, PCV13)
    Titievsky, Lina
    Esposito, Daina B.
    Hawes, Jennifer C. L.
    Maroko, Robert
    Hollingsworth, Rosalind C.
    Holick, Crystal N.
    Lanes, Stephan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 183 - 184
  • [9] Impact of private use of the 13-valent pneumococcal conjugate vaccine (PCV13) on pneumococcal carriage among Portuguese children living in urban and rural regions
    Felix, Sofia
    Handem, Sara
    Nunes, Sonia
    Paulo, Ana Cristina
    Candeias, Catarina
    Valente, Carina
    Simoes, Alexandra S.
    Almeida, Sonia T.
    Tavares, Debora A.
    Brito-Avo, Antonio
    de Lencastre, Herminia
    Sa-Leao, Raquel
    VACCINE, 2021, 39 (32) : 4524 - 4533
  • [10] Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States
    Rubin, Jaime L.
    McGarry, Lisa J.
    Strutton, David R.
    Klugman, Keith P.
    Pelton, Stephen I.
    Gilmore, Kristen E.
    Weinstein, Milton C.
    VACCINE, 2010, 28 (48) : 7634 - 7643